The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Progression-free survival (PFS) with maintenance treatment with bevacizumab (B) in patients with responding mCRC after first-line chemotherapy (CT) plus B.
Maria Agnese Fabbri
No relevant relationships to disclose
Maria Fabbri
Disclosure not yet available
Fabrizio Nelli
No relevant relationships to disclose
Luca Moscetti
No relevant relationships to disclose
Enrico Cortesi
No relevant relationships to disclose
Teresa Gamucci
No relevant relationships to disclose
Isabella Sperduti
No relevant relationships to disclose
Daniela Franco
No relevant relationships to disclose
Ida Pavese
No relevant relationships to disclose
Roberta Grande
No relevant relationships to disclose
Daniele Alesini
No relevant relationships to disclose
Enzo Ruggeri
No relevant relationships to disclose